natgillin/translations-raw huggingface dataset:
In a controlled clinical trial of two years duration in adult rheumatoid arthritis patients, the combination of LIFMIOR and methotrexate did not result in unexpected safety findings, and the safety profile of LIFMIOR when given in combination with methotrexate was similar to the profiles reported in studies of LIFMIOR and methotrexate alone. 
V dveletnem nadzorovanem kliničnem preskušanju pri odraslih bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z zdravilom LIFMIOR in metotreksatom nobenih nepričakovanih ugotovitev glede varnosti; varnostni profil zdravila LIFMIOR pri kombiniranem zdravljenju z metotreksatom je bil podoben varnostnemu profilu, ki je bil ugotovljen pri monoterapiji z zdravilom LIFMIOR oziroma metotreksatom.
Non-radiographic axial spondyloarthritis 
Radiografsko nezaznavni aksialni spondilartritis
The safety and efficacy profiles of the 50 mg once weekly and 25 mg twice weekly regimens were similar. 
Profil varnosti in učinkovitosti je bil pri režimu dajanja 50 mg enkrat na teden podoben kot pri režimu dajanja 25 mg dvakrat na teden.
LIFMIOR is available in strengths of 10, 25 and 50 mg. 
Zdravilo LIFMIOR je na voljo v jakostih 10, 25 in 50 mg.
Clinical responses among nr-AxSpa patients who received LIFMIOR were apparent at the time of the first visit (2 weeks) and were maintained through 2 years of therapy. 
Klinični odzivi pri bolnikih z nr-AxSpa, ki so prejemali LIFMIOR, so bili vidni ob prvem obisku (po 2 tednih) in so se vzdrževali med celotnim 2-letnim zdravljenjem.
• Place the filled syringe on the clean, flat surface. 
Napolnjeno injekcijsko brizgo položite na čisto in ravno površino.
Purple needle safety shield extends to cover needle 
Vijolični varnostni ščit igle se podaljša in prekrije iglo.
If you are not sure, please talk to your doctor. 
Če ste v dvomih, se posvetujte z zdravnikom.
Your doctor will determine if preventive treatment for chickenpox is appropriate. 
Zdravnik bo presodil, ali je potrebno preventivno zdravljenje proti noricam.
In another open-label single-arm study, 60 patients with extended oligoarthritis (15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to 17 years old) were treated with LIFMIOR at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) administered weekly for 12 weeks. 
V drugi odprti študiji z eno skupino se je z zdravilom LIFMIOR v odmerku 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden zdravilo 60 bolnikov z razširjenim oligoartritisom (15 bolnikov, starih od 2 do 4 leta, 23 bolnikov, starih od 5 do 11 let, in 22 bolnikov, starih od 12 do 17 let), 38 bolnikov z artritisom, povezanim z entezitisom (starih od 12 do 17 let) in 29 bolnikov s psoriatičnim artritisom (starih od 12 do 17 let).
Patients in this study received a dose of 25 mg or 50 mg LIFMIOR, or placebo twice a week for 12 weeks and then all patients received open-label 25 mg LIFMIOR twice weekly for an additional 24 weeks. 
Bolniki v tej študiji so dobivali odmerek 25 mg ali 50 mg zdravila LIFMIOR ali placebo dvakrat na teden 12 tednov, potem pa so vsi bolniki v odprtem delu dobivali 25 mg zdravila LIFMIOR dvakrat na teden dodatnih 24 tednov.
In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of LIFMIOR and methotrexate did not result in unexpected safety findings, and the safety profile of LIFMIOR when given in combination with methotrexate was similar to the profiles reported in studies of LIFMIOR and methotrexate alone. 
V dveletnem nadzorovanem kliničnem preskušanju pri bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z zdravilom LIFMIOR in metotreksatom nobenih nepričakovanih ugotovitev glede varnosti; varnostni profil zdravila LIFMIOR pri kombiniranem zdravljenju z metotreksatom je bil podoben varnostnemu profilu, ki je bil ugotovljen pri monoterapiji z zdravilom LIFMIOR oziroma metotreksatom.
Etanercept is a competitive inhibitor of TNF-binding to its cell surface receptors and thereby inhibits the biological activity of TNF. 
Etanercept je kompetitivni antagonist vezave TNF na receptorje na površini celice in torej zavira biološko aktivnost TNF.
Pre-filled pen (MYCLIC) containing a pre-filled syringe of LIFMIOR. 
Napolnjen injekcijski peresnik (MYCLIC), ki vsebuje napolnjeno injekcijsko brizgo zdravila LIFMIOR.
Withdrawing the LIFMIOR solution from the vial 
Jemanje raztopine zdravila LIFMIOR iz viale
Abbreviation: sPGA-static Physician Global Assessment a. p < 0.0001 compared with placebo 
sPGA “čisto” ali “minimalno”, n (%) Okrajšava: sPGA-statična zdravnikova splošna ocena a. p < 0,0001 v primerjavi s placebom
The efficacy of LIFMIOR in ankylosing spondylitis was assessed in 3 randomised, double-blind studies comparing twice weekly administration of 25 mg LIFMIOR with placebo. 
Učinkovitost zdravila LIFMIOR pri bolnikih z ankilozirajočim spondilitisom je bila ocenjena v 3 randomiziranih dvojno slepih študijah, kjer so primerjali uporabo 25 mg zdravila LIFMIOR dvakrat tedensko s placebom.
Responses were measured using the ACR Pedi 30 ), defined as ≥ 30% improvement in at least three of six and ≥ 30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR). 
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Similarly, the significant advantages for LIFMIOR monotherapy compared with methotrexate monotherapy were also observed after 24 months. 
Podobno so po 24 mesecih ugotovili tudi pomembne prednosti monoterapije z zdravilom LIFMIOR pred monoterapijo z metotreksatom.
Your symptoms may return upon discontinuation. 
Po prekinitvi uporabe se lahko vaši simptomi ponovijo.
There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates risk estimation. 
Pri bolnikih, ki imajo revmatoidni artritis z dolgotrajno in zelo aktivno vnetno boleznijo, je osnovno tveganje za pojav limfomov in levkemije povečano, kar oteži oceno tveganja.
The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks. 
Priporočeni odmerek je 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden do največ 24 tednov.
Do not touch the needle or allow it to touch any surface. 
Igle se ne dotikajte in pazite, da ne pride v stik z ničemer.
Radiographic Progression: Comparison of LIFMIOR vs Methotrexate in Patients with RA of <3 Years Duration 
Radiografsko napredovanje: primerjava zdravila LIFMIOR z metotreksatom pri bolnikih z RA, ki je trajal < 3 leta
LIFMIOR should not normally be used in children with polyarthritis or extended oligoarthritis below the age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12 years, or in children with psoriasis below the age of 6 years. 
Pri otrocih s poliartritisom ali z razširjenim oligoartritisom, mlajših od 2 let, otrocih z artritisom, povezanim z entezitisom, ali s psoriatičnim artritisom, mlajših od 12 let, in otrocih s psoriazo, mlajših od 6 let, se zdravila LIFMIOR običajno ne sme uporabljati.
For children, remove only the portion of liquid as directed by your child's doctor. 
Za odraslega bolnika izvlecite celotni volumen raztopine, za otroka pa le toliko, kot je določil njegov zdravnik.
Infection (including upper respiratory tract infection, bronchitis, cystitis, skin infection)* 
Infekcijske in parazitske bolezni okužba (vključno z okužbo zgornjih dihal, bronhitisom, cistitisom in okužbo kože)*
Study 3 
Študija 3
Autoantibodies 
Tvorba avtoprotiteles
Lightly pinching the skin around the injection site between the thumb and index finger of your free hand may make the injection easier and more comfortable. 
Injiciranje utegne biti enostavnejše in manj neprijetno, če boste okoli mesta injiciranja s prosto roko narahlo stisnili kožo s palcem in kazalcem.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including LIFMIOR, has been reported. 
Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B (HBV) in so se zdravili z antagonisti TNF, vključno z zdravilom LIFMIOR, so poročali o reaktivaciji hepatitisa B. Poročila vključujejo tudi reaktivacijo hepatitisa B pri anti-HBc pozitivnih, vendar HBsAg negativnih bolnikih.
• To open the plastic container, hold the short, wide end in one hand. 
Plastično embalažo odprete tako, da z eno roko primete za krajši, širši del. Z drugo roko pa primete za daljši del embalaže.
8 pre-filled syringes 8 alcohol swabs 
8 napolnjenih injekcijskih brizg 8 alkoholnih blazinic
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to LIFMIOR. 
Med obdobjem randomiziranega prekinjanja zdravljenja se je recidiv bolezni (izguba odziva PASI 75) pojavil pri pomembno več bolnikih, ki so bili ponovno v skupini s placebom, kot pri bolnikih, ki so bili ponovno v skupini z zdravilom LIFMIOR.
Doing so could cause the liquid to leak out. 
V tem primeru lahko pride do uhajanja tekočine iz brizge.
The MYCLIC pen contains a clear, colourless to pale yellow or pale brown, solution for injection. 
Injekcijski peresnik MYCLIC vsebuje bistro, brezbarvno do bledo rumeno oziroma bledo rjavo raztopino za injiciranje.
The syringes are type I glass. 
Brizge so steklene (steklo tipa I).
The efficacy of LIFMIOR in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was assessed in a randomised, 12-week double-blind, placebo-controlled study. 
Odrasli bolniki z radiografsko nezaznavnim aksialnim spondilartritisom Učinkovitost zdravila LIFMIOR so pri bolnikih z radiografsko nezaznavnim aksialnim spondilartritisom (nr-AxSpa) ocenili v randomizirani 12-tedenski, dvojno slepi, s placebom nadzorovani študiji.
If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately. 
Če se med zdravljenjem ali po njem pojavijo simptomi tuberkuloze (na primer trdovraten kašelj, hujšanje, apatija, blaga vročina) ali kakšne druge okužbe, to nemudoma povejte zdravniku.
Do not mix the LIFMIOR solution with any other medicine. 
Raztopine zdravila LIFMIOR ne smete mešati z nobenim drugim zdravilom.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2) 
Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
• While holding the syringe upright, remove any air bubbles by slowly pushing on the plunger until the air is removed (see Diagram 16). 
Brizgo obrnite navzgor in odstranite zrak iz nje tako, da počasi pritiskate na bat, dokler ni odstranjen ves zrak (glejte sliko 16).
Doses of 10 mg or 25 mg LIFMIOR were administered subcutaneously (SC) twice a week for up to 24 months. 
Odmerki 10 mg ali 25 mg zdravila LIFMIOR so bili dani subkutano (s.c.) 2-krat tedensko do 24 mesecev.
After taking a syringe from the refrigerator, wait approximately 15-30 minutes to allow the LIFMIOR solution in the syringe to reach room temperature. 
Ko brizgo vzamete iz hladilnika, počakajte približno 15 do 30 minut, da se raztopina zdravila LIFMIOR v brizgi segreje na sobno temperaturo.
The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly as a subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of 50 mg per dose) given once weekly. 
Priporočeni odmerek je 0,4 mg/kg telesne mase (do največ 25 mg na odmerek) 2-krat na teden v obliki subkutane injekcije z razmikom med odmerki od 3 do 4 dni ali 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden.
• If you have any further questions, ask your doctor, pharmacist or nurse. 
Če imate dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Rates of serious adverse events and serious infections did not increase with long-term exposure. 
Pri dolgotrajni izpostavljenosti zdravilu se delež resnih neželenih učinkov in hudih okužb ni povečal.
• The pre-filled syringe is for single-use administration only. 
Napolnjena injekcijska brizga je namenjena le za enkratno uporabo.
Differences from adults and other special considerations are discussed in the following paragraphs. 
Spodaj opisujemo razlike glede na odrasle bolnike in druge posebnosti.
Some vaccines, such as oral polio vaccine, should not be given while using LIFMIOR. 
Med zdravljenjem z zdravilom LIFMIOR nekaterih cepiv, npr. peroralnega cepiva proti otroški paralizi, ni dovoljeno uporabljati.
Method and route of administration 
Način in pot uporabe
NEVER re-cap a needle. 
Na iglo NIKOLI ponovno ne nameščajte pokrovčka.
In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and radiographic progression in RA patients treated with LIFMIOR alone (25 mg twice weekly), methotrexate alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of LIFMIOR and methotrexate initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6 months to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 disease-modifying antirheumatic drug (DMARD) other than methotrexate. 
V drugi dvojno slepi randomizirani študiji, nadzorovani z učinkovino, so primerjali klinično učinkovitost, varnost in radiografsko napredovanje pri bolnikih z revmatoidnim artritisom, ki so jih zdravili samo z zdravilom LIFMIOR (25 mg 2-krat na teden), samo z metotreksatom (7,5 do 20 mg na teden, mediani odmerek 20 mg) ali z zdravilom LIFMIOR in metotreksatom (s sočasnim začetkom), in sicer pri 682 odraslih bolnikih z aktivnim revmatoidnim artritisom, pri katerih je bolezen trajala od 6 mesecev do 20 let (mediano trajanje 5 let) in pri katerih je bil odziv na najmanj eno od imunomodulirajočih antirevmatičnih zdravil (DMARD), razen metotreksata, manj kot zadovoljiv.
• Hepatitis C: Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with LIFMIOR in case the infection worsens. 
Hepatitis C: Povejte zdravniku, če imate vi ali vaš otrok hepatitis C. Zdravnik bo morda želel spremljati zdravljenje z zdravilom LIFMIOR za primer, če bi se okužba poslabšala.
Do not inject into areas where the skin is tender, bruised, red, or hard. 
NE injicirajte v predelih, kjer je koža občutljiva, poškodovana, rdeča ali otrdela.
What LIFMIOR contains 
Kaj vsebuje zdravilo LIFMIOR
Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of continued LIFMIOR therapy in patients who do not respond within 3 months of initiating LIFMIOR therapy. 
Pri bolnikih z juvenilnim idiopatskim artritisom, ki se v 3 mesecih po uvedbi zdravljenja z zdravilom LIFMIOR ne odzovejo na zdravljenje, niso izvedli študij za ovrednotenje učinka kontinuiranega zdravljenja z zdravilom LIFMIOR.
Etanercept crosses the placenta and has been detected in the serum of infants born to female patients treated with LIFMIOR during pregnancy. 
Zaznali so ga v serumu dojenčkov, rojenim bolnicam, ki so se med nosečnostjo zdravile z zdravilom LIFMIOR.
Carefully dispose of any LIFMIOR solution that has not been injected within 6 hours. 
Raztopino zdravila LIFMIOR, ki je v 6 urah po pripravi niste injicirali, previdno zavrzite.
Patients should be tested for HBV infection before initiating treatment with LIFMIOR. 
Pred uvedbo zdravljenja z zdravilom LIFMIOR je treba bolnike testirati na okužbo s HBV.
The needle cover of the pre-filled syringe contains latex (dry natural rubber) that may cause hypersensitivity reactions when handled by, or when LIFMIOR is administered to, persons with known or possible latex sensitivity. 
Pokrovček igle napolnjene injekcijske brizge vsebuje lateks (posušen naravni kavčuk), ki lahko povzroči preobčutljivostne reakcije, če z zdravilom LIFMIOR ravna oseba z znano ali možno preobčutljivostjo na lateks ali če ga damo taki osebi.
• While still in the plastic package, place the vial adaptor on top of the LIFMIOR vial so that the vial adaptor spike is centered within the raised circle on top of the vial stopper (see Diagram 2). 
Adapter viale pustite v plastični embalaži in ga položite na vrh viale zdravila LIFMIOR tako, da bo konica adapterja viale poravnana z dvignjenim delom zamaška na viali (glejte sliko 2).
Additionally, the pharmacokinetics of LIFMIOR in rheumatoid arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar. 
Farmakokinetika zdravila LIFMIOR pri bolnikih z revmatoidnim artritisom, ankilozirajočim spondilitisom in psoriazo v plakih je podobna.
Starting from one of the top corners, pull back the paper cover from the top and sides of the tray. 
Potegnite papirnato plast z vrha in strani pretisnega omota, tako da začnete v enem od zgornjih kotov.
Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with LIFMIOR. 
Pri bolnikih, zdravljenih z zdravilom LIFMIOR, so v obdobju trženja poročali o zelo redkih primerih karcinoma Merklovih celic.
Responses of Patients with Psoriatic Arthritis in a PlaceboControlled Trial Percent of Patients Placebo 
Odzivi bolnikov s psoriatičnim artritisom v preskušanju, nadzorovanem s placebom Odstotek bolnikov Placebo
Your doctor may decide if the child needs less anti-diabetic medicine while taking LIFMIOR. 
Zdravnik lahko odloči, da bo otrok med jemanjem zdravila LIFMIOR potreboval manj zdravila za sladkorno bolezen.
Renal and hepatic impairment No dose adjustment is required. 
Bolniki z okvaro ledvic ali jeter Prilagajanje odmerka ni potrebno.
Abbreviation: sPGA-static Physician Global Assessment. 
b. Dermatološka statična splošna ocena.
These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy. 
Take bolnike je treba ves čas zdravljenja in še več tednov po prekinitvi zdravljenja spremljati glede znakov in simptomov aktivne okužbe s HBV. O sočasnem protivirusnem zdravljenju in zdravljenju z antagonisti TNF pri bolnikih, okuženih s HBV, ni zadostnih podatkov.
You will be instructed by the child's doctor or his/her assistant on the technique of giving an injection and on the amount to be given to the child. Do not attempt to administer an injection until you are sure that you understand how to prepare and give the injection. 
Zdravnik vašega otroka ali medicinska sestra vas bosta natančno poučila o pravilni tehniki dajanja injekcij otroku in o količini zdravila, ki ga morate dati otroku.
Preparing the LIFMIOR dose for injection 
Priprava odmerka zdravila LIFMIOR za injiciranje
If you or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor immediately. 
Če se pri vas ali vašem otroku razvijejo simptomi okužbe, na primer vročina, mrzlica ali kašelj, nemudoma obvestite zdravnika.
DAS Baseline scoreb Week 52 scoreb 
DAS ocena v izhodišču ocena po 52 tednih remisija
• if you or the child have, or are at risk of developing a serious blood infection called sepsis. 
če imate vi ali otrok resno okužbo krvi (sepso) ali če pri vas ali otroku obstaja tveganje za njen pojav.
• Place the vial upright on a clean, flat surface. 
Vialo postavite pokonci na ravno, čisto površino.
Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have been reported in patients treated with LIFMIOR. 
Pri bolnikih, ki so bili zdravljeni z zdravilom LIFMIOR, so poročali o redkih primerih pancitopenije in zelo redkih primerih aplastične anemije, tudi s smrtnim izidom.
Radiographic progression at 12 months was significantly less in the LIFMIOR group than in the methotrexate group, while the combination was significantly better than either monotherapy at slowing radiographic progression (see figure below). 
Po 12 mesecih zdravljenja je bilo radiografsko napredovanje pri bolnikih, ki so jih zdravili z zdravilom LIFMIOR, statistično pomembno počasnejše kot pri bolnikih, ki so jih zdravili z metotreksatom; kombinacija obeh zdravil pa je radiografsko napredovanje upočasnila statistično pomembno učinkoviteje kot eno samo zdravilo (glejte spodnjo sliko).
After taking a pre-filled pen from the refrigerator, wait approximately 15-30 minutes to allow the LIFMIOR solution in the pen to reach room temperature. 
Ko napolnjeni peresnik vzamete iz hladilnika, počakajte približno 15 do 30 minut, da se raztopina zdravila LIFMIOR v peresniku segreje na sobno temperaturo.
Slight bleeding may occur. 
Lahko pride do rahle krvavitve.
Physicians should exercise caution when considering the use of LIFMIOR in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections, such as advanced or poorly controlled diabetes. 
Zdravniki morajo biti zelo previdni, kadar se odločajo za zdravljenje s tem zdravilom pri bolnikih s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali z drugimi osnovnimi stanji (kot je na primer napredovala ali neurejena sladkorna bolezen), ki bi lahko povečala dovzetnost bolnikov za okužbe.
Each pack contains 4 vials, 4 pre-filled syringes of water for injections, 4 needles, 4 vial adaptors and 8 alcohol swabs. 
Eno pakiranje vsebuje 4 viale, 4 napolnjene injekcijske brizge z vodo za injekcije, 4 injekcijske igle, 4 adapterje za vialo in 8 alkoholnih blazinic.
The pre-filled syringe is available in dose strengths of 25 mg and 50 mg. 
Napolnjena injekcijska brizga je na voljo v jakostih 25 mg in 50 mg.
With twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high as those observed after single doses. 
Pričakovati je, da bodo koncentracije v stanju dinamičnega ravnovesja po odmerjanju 2-krat tedensko približno dvakrat večje od tistih, ki jih izmerimo po enkratnem odmerku.
Solvent Water for injections 
Vehikel voda za injekcije
8 alcohol swabs 
8 alkoholnih blazinic
Each vial of LIFMIOR 10 mg powder and solvent for solution for injection for paediatric use contains 10 mg of etanercept. 
Ena viala zdravila LIFMIOR 10 mg prašek in vehikel za raztopino za injiciranje za uporabo pri otrocih vsebuje 10 mg etanercepta.
If the child develops symptoms of an infection such as fever, chills or cough, notify your doctor immediately. 
Če se pri vašem otroku razvijejo simptomi okužbe, na primer vročina, mrzlica ali kašelj, nemudoma obvestite zdravnika.
70b a: 25 mg LIFMIOR SC twice weekly b: p < 0.001, LIFMIOR vs. placebo c: p < 0.01, LIFMIOR vs. placebo 
PsARC 3. mesec 6. mesec a: 25 mg zdravila LIFMIOR subkutano dvakrat na teden b: p < 0,001, zdravilo LIFMIOR v primerjavi s placebom c: p < 0,01, zdravilo LIFMIOR v primerjavi s placebom
• For enthesitis-related arthritis in patients from the age of 12 years when other widely used treatments have not worked well enough or are not suitable for them 
• za zdravljenje artritisa, povezanega z entezitisom, pri bolnikih, starejših od 12 let, če zdravljenje z običajnimi oblikami zdravljenja ni bilo uspešno ali jih bolniki niso prenašali.
The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate and sodium phosphate dibasic dihydrate, and water for injections. 
Pomožne snovi so: saharoza, natrijev klorid, L-argininijev klorid, natrijev dihidrogenfosfat dihidrat, natrijev hidrogenfosfat dihidrat in voda za injekcije.
ASAS 20 2 weeks 
ASAS 20 2 tedna 3 meseci 6 mesecev a